Published in J Mol Biol on July 21, 2006
Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol (2009) 3.05
Crystal structure of human prion protein bound to a therapeutic antibody. Proc Natl Acad Sci U S A (2009) 1.29
Synthetic antibody libraries focused towards peptide ligands. J Mol Biol (2008) 1.15
Affinity maturation of antibodies assisted by in silico modeling. Proc Natl Acad Sci U S A (2008) 1.09
Improving the species cross-reactivity of an antibody using computational design. Bioorg Med Chem Lett (2009) 0.90
Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting. J Mol Biol (2010) 0.89
Single-chain fragment variable passive immunotherapies for neurodegenerative diseases. Int J Mol Sci (2013) 0.84
Selection and structural analysis of de novo proteins from an alpha3beta3 genetic library. Protein Sci (2009) 0.83
Prion Protein-Antibody Complexes Characterized by Chromatography-Coupled Small-Angle X-Ray Scattering. Biophys J (2015) 0.83
Development of Next-Generation Peptide Binders Using In vitro Display Technologies and Their Potential Applications. Front Immunol (2013) 0.81
Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice. Prion (2007) 0.80
Single-chain Fv phage display propensity exhibits strong positive correlation with overall expression levels. BMC Biotechnol (2008) 0.78
Generation of recombinant antibodies to rat GABAA receptor subunits by affinity selection on synthetic peptides. PLoS One (2014) 0.78
In vitro selection of fab fragments by mRNA display and gene-linking emulsion PCR. J Nucleic Acids (2012) 0.78
Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes. Prion (2010) 0.77
Modeling amyloid-beta as homogeneous dodecamers and in complex with cellular prion protein. PLoS One (2012) 0.76
The clinical potential of circulating tumor cells; the need to incorporate a modern "immunological cocktail" in the assay. Cancers (Basel) (2013) 0.76
Development of anti-bovine IgA single chain variable fragment and its application in diagnosis of foot-and-mouth disease. Eur J Microbiol Immunol (Bp) (2014) 0.76
Prion diseases: immunotargets and therapy. Immunotargets Ther (2016) 0.75
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Synthetic mammalian prions. Science (2004) 7.35
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol (2006) 5.28
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Toward an AIDS vaccine. Science (2008) 4.83
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog (2010) 4.47
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 4.45
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray. Genome Biol (2003) 4.24
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
HIV vaccine research: the way forward. Science (2008) 3.86
Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 3.67
Evidence for assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad Sci U S A (2004) 3.64
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron (2002) 3.36
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res (2003) 3.34
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol (2004) 3.34
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A (2012) 3.30
Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell (2005) 3.29
Prions. Cold Spring Harb Perspect Biol (2011) 3.17
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Automated extraction of mutation data from the literature: application of MuteXt to G protein-coupled receptors and nuclear hormone receptors. Bioinformatics (2004) 3.03
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 3.03
Small-molecule aggregates inhibit amyloid polymerization. Nat Chem Biol (2008) 2.98
Pathway complexity of prion protein assembly into amyloid. J Biol Chem (2002) 2.96
Structural studies of the scrapie prion protein by electron crystallography. Proc Natl Acad Sci U S A (2002) 2.91
Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol (2003) 2.81
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A (2010) 2.77
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol (2010) 2.76
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci U S A (2006) 2.69
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci U S A (2011) 2.58
Ca(2+)-regulated structural changes in troponin. Proc Natl Acad Sci U S A (2005) 2.56
Transfer of scrapie prion infectivity by cell contact in culture. Curr Biol (2002) 2.54
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A (2010) 2.51
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol (2010) 2.47
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Design and construction of diverse mammalian prion strains. Proc Natl Acad Sci U S A (2009) 2.41
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol (2009) 2.41
Analysis of proteome dynamics in the mouse brain. Proc Natl Acad Sci U S A (2010) 2.37
Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci U S A (2012) 2.36
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol (2003) 2.34
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
Prion detection by an amyloid seeding assay. Proc Natl Acad Sci U S A (2007) 2.34
A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol (2004) 2.33
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol (2003) 2.31
Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem (2005) 2.29
Strain-specified characteristics of mouse synthetic prions. Proc Natl Acad Sci U S A (2005) 2.25
Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol (2002) 2.24